ClinicalTrials.gg
CompletedNCT01414855Updated Sep 29, 2026Results posted

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

A Phase 2 interventional study of obinutuzumab and cyclophosphamide in Lymphoma, B-Cell, sponsored by Genentech, Inc.. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Updated Sep 29, 2026Posted results revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 398 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
81st of 380
100 · median 37
Started
2011
with 11 others
Phase 2
112 of 398
23 open now
Registered
88th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 81st largest by enrollment of the 380 interventional ones that give a count, is one of 12 that started in 2011, is one of 112 in phase 2, and was the 88th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab [RO5072759 (GA101)] in combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy in patients with advanced diffuse large B-cell lymphoma. Patients will receive 8 cycles of obinutuzumab (1000 mg intravenously on Day 1 of each 21-day cycle, during Cycle 1 obinutuzumab will also be infused on Days 8 and 15) in combination with CHOP chemotherapy on Day 1 of cycles 1 to 6. A substudy will investigate the drug-drug interaction of obinutuzumab with CHOP chemotherapy agents. For the substudy, an additional cohort of approximately 15 patients are planned to be enrolled at a subset of investigational sites.

03

Conditions studied

  • Lymphoma, B-Cell

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥18 years of age
  • Previously untreated cluster of differentiation antigen 20 (CD20)-positive diffuse large B-cell lymphoma
  • Ann Arbour Stage III/IV and bulky II (mass >10 cm)
  • At least one bi-dimensionally defined as >1.5 cm in its largest dimension by CT scan
  • (ECOG) performance status 0, 1 or 2
  • ≥50%
  • Adequate hematologic function

Exclusion criteria

Exclusion Criteria:

  • Transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or immunotherapy
  • Prior therapy for diffuse large B-cell lymphoma except for nodal or local irradiation
  • Central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma, primary cutaneous lymphoma, primary effusion lymphoma
  • Patients who received cytotoxic drugs or rituximab as part of their treatment for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody
  • Chemotherapy or other therapy within 28 days prior to the start of Cycle 1
  • to any of the individual components of CHOP, including prior receipt of anthracyclines
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  • History of other , except for curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix, or malignancy treated with or without curative intent and in remission without treatment for ≥2 years prior to enrolment
  • Positive for , , (HIV) or human T-cell leukemia virus (HTLV-1) infection
  • Pregnant or lactating women
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    obinutuzumab + CHOP

    Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.

    Drug: obinutuzumab · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone · Drug: vincristine

Interventions

  • 1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.

  • 750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.

  • 50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.

  • 100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.

  • 1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment

    Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). CR is the disappearance of all evidence of disease.

    Time frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

  2. Overall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment

    Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, FDG-PET and computed tomography (CT). CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites.

    Time frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

Secondary outcomes

  1. Complete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment

    Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease.

    Time frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

  2. Overall Response Rate (ORR) as Assessed by the IRF at the End of Treatment

    Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites.

    Time frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

  3. Progression-Free Survival (PFS) as Assessed by the Investigator

    PFS was defined as the time from the date of the first dose of study treatment until the date of disease progression, relapse, or death from any cause.

    Time frame: From the first dose of study treatment to PFS assessment (up to 64 months)

  4. Duration of Response (DOR)

    DOR is defined as first occurrence of documented response (CR or PR) until the first occurrence of relapse or progression or death of any cause. CR: disappearance of all evidence of disease. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites.

    Time frame: From the response assessment to relapse, progression, or death (up to 64 months)

  5. Percentage of Participants With Adverse Events as a Measure of Safety

    An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug or other protocol-imposed intervention. Preexisting conditions that worsened during the study were reported as adverse events.

    Time frame: From the first dose of study treatment to end of study (up to 5 years 4 months)

  6. Number of Participants With Grade 3 to 4 Infusion-Related (IRR) Adverse Events (AE) in Participants Receiving Shorter Duration Infusion (SDI)

    SDI 120 is a shorter duration infusion of 120 minutes and SDI 90 is shorter duration infusion of 90 minutes. Grade 3 IRR AE: Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Grade 4 IRR AE: Life-threatening consequences; urgent intervention indicated.

    Time frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

  7. Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) for Obinutuzumab

    Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL).

    Time frame: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

  8. Pharmacokinetics: Terminal Half-Life (t1/2) for Obinutuzumab

    T1/2 is the time required for the concentration of the drug to reach half of its original value. Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in days

    Time frame: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

  9. Pharmacokinetics: Clearance (Cl) for Obinutuzumab

    Cl is the volume of serum cleared of the drug per unit of time. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters/day (mL/day).

    Time frame: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

  10. Pharmacokinetics: Volume of Distribution (V) for Obinutuzumab

    V is the apparent volume in which a drug is distributed in the body. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters (mL).

    Time frame: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

  11. Pharmacokinetics: Area Under the Concentration-Time Curve 7 Day (AUC7day)

    Blood was collected for PK parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in in day times micrograms per milliliter (day\*μg/mL).

    Time frame: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

  12. Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Depletion

    B-cell depletion was defined as a CD19 result \< 0.07 × 10\^9/L after at least one dose of study drug had been administered. Participants were evaluated during a 30-month post-treatment follow-up period following the completion of active study treatment (Cycle 8 \[each cycle = 21 days\]). Total study duration across active treatment and follow-up was up to approximately 5 years.

    Time frame: From end of study treatment up to approximately 30 months

  13. Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Recovery

    B-cell recovery was defined as a CD19 result \>= 0.07 × 10\^9/L, where CD19 was previously depleted. B-cell recovery was only considered possible following the last dose of study treatment. The number of participants with B-cell recovery from End of Treatment to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) \[PD before B-cell recovery or PD within 45 days after recovery\] or Recovery without PD. PD required one of the following: 50% increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50% increase in the longest diameter of any previous site of lymphadenopathy, 50% increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.

    Time frame: Up to approximately 30 months

07

Results

Posted Mar 19, 2015

Participant flow

Participant flow — Overall Study
MilestoneObinutuzumab + CHOP
Started100
Completed71
Not completed29
Withdrew: Death17
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject7

Outcome measures

PrimaryComplete Response (CR) Rate as Assessed by the Investigator at the End of Treatment

Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). CR is the disappearance of all evidence of disease.

Time frame:
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
Reported as:
Number · percentage of participants
Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment
percentage of participantsObinutuzumab + CHOP
Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment55.0 (44.73 to 64.97)
PrimaryOverall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment

Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, FDG-PET and computed tomography (CT). CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites.

Time frame:
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment
percentage of participantsObinutuzumab + CHOP
Overall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment82.0 (73.05 to 88.97)
SecondaryComplete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment

Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease.

Time frame:
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
Reported as:
Number · percentage of participants
Complete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment
percentage of participantsObinutuzumab + CHOP
Complete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment58.0 (47.71 to 67.80)
SecondaryOverall Response Rate (ORR) as Assessed by the IRF at the End of Treatment

Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites.

Time frame:
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) as Assessed by the IRF at the End of Treatment
percentage of participantsObinutuzumab + CHOP
Overall Response Rate (ORR) as Assessed by the IRF at the End of Treatment75.0 (65.34 to 83.12)
SecondaryProgression-Free Survival (PFS) as Assessed by the Investigator

PFS was defined as the time from the date of the first dose of study treatment until the date of disease progression, relapse, or death from any cause.

Time frame:
From the first dose of study treatment to PFS assessment (up to 64 months)
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by the Investigator
monthsObinutuzumab + CHOP
Progression-Free Survival (PFS) as Assessed by the Investigator48.3 (46.1 to 58.2)
SecondaryDuration of Response (DOR)

DOR is defined as first occurrence of documented response (CR or PR) until the first occurrence of relapse or progression or death of any cause. CR: disappearance of all evidence of disease. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites.

Time frame:
From the response assessment to relapse, progression, or death (up to 64 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsObinutuzumab + CHOP
Duration of Response (DOR)45.6 (43.1 to 55.7)
SecondaryPercentage of Participants With Adverse Events as a Measure of Safety

An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug or other protocol-imposed intervention. Preexisting conditions that worsened during the study were reported as adverse events.

Time frame:
From the first dose of study treatment to end of study (up to 5 years 4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events as a Measure of Safety
percentage of participantsObinutuzumab + CHOP
Percentage of Participants With Adverse Events as a Measure of Safety100.0
SecondaryNumber of Participants With Grade 3 to 4 Infusion-Related (IRR) Adverse Events (AE) in Participants Receiving Shorter Duration Infusion (SDI)

SDI 120 is a shorter duration infusion of 120 minutes and SDI 90 is shorter duration infusion of 90 minutes. Grade 3 IRR AE: Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Grade 4 IRR AE: Life-threatening consequences; urgent intervention indicated.

Time frame:
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
Reported as:
Number · participants
Number of Participants With Grade 3 to 4 Infusion-Related (IRR) Adverse Events (AE) in Participants Receiving Shorter Duration Infusion (SDI)
participantsObinutuzumab + CHOP
SDI 1200
SDI 900
SecondaryPharmacokinetics (PK): Maximum Concentration Observed (Cmax) for Obinutuzumab

Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL).

Time frame:
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
Reported as:
Mean · μg/mL
Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) for Obinutuzumab
μg/mLObinutuzumab + CHOP
Cycle 1297 ± 110
Cycle 8574 ± 183
SecondaryPharmacokinetics: Terminal Half-Life (t1/2) for Obinutuzumab

T1/2 is the time required for the concentration of the drug to reach half of its original value. Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in days

Time frame:
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
Reported as:
Mean · days
Pharmacokinetics: Terminal Half-Life (t1/2) for Obinutuzumab
daysObinutuzumab + CHOP
Cycle 16.04 ± 1.54
Cycle 823 ± 15.9
SecondaryPharmacokinetics: Clearance (Cl) for Obinutuzumab

Cl is the volume of serum cleared of the drug per unit of time. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters/day (mL/day).

Time frame:
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
Reported as:
Mean · mL/day
Pharmacokinetics: Clearance (Cl) for Obinutuzumab
mL/dayObinutuzumab + CHOP
Cycle 1456 ± 254
Cycle 8143 ± 59.8
SecondaryPharmacokinetics: Volume of Distribution (V) for Obinutuzumab

V is the apparent volume in which a drug is distributed in the body. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters (mL).

Time frame:
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
Reported as:
Mean · mL
Pharmacokinetics: Volume of Distribution (V) for Obinutuzumab
mLObinutuzumab + CHOP
Cycle 14580 ± 2450
Cycle 89210 ± 17000
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve 7 Day (AUC7day)

Blood was collected for PK parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in in day times micrograms per milliliter (day\*μg/mL).

Time frame:
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
Reported as:
Mean · day*μg/mL
Pharmacokinetics: Area Under the Concentration-Time Curve 7 Day (AUC7day)
day*μg/mLObinutuzumab + CHOP
Cycle 11320 ± 440
Cycle 83300 ± 1130
SecondaryPharmacodynamics: Number of Participants With Peripheral Blood B-cell Depletion

B-cell depletion was defined as a CD19 result \< 0.07 × 10\^9/L after at least one dose of study drug had been administered. Participants were evaluated during a 30-month post-treatment follow-up period following the completion of active study treatment (Cycle 8 \[each cycle = 21 days\]). Total study duration across active treatment and follow-up was up to approximately 5 years.

Time frame:
From end of study treatment up to approximately 30 months
Reported as:
Number · Participants
Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Depletion
ParticipantsObinutuzumab + CHOP
End of Treatment69
Up to 6 Months Follow-up69
Within 6-12 Months of Follow-up28
Within 12-18 Months of Follow-up10
Within 18-24 Months of Follow-up5
Within 24-30 Months of Follow-up0
After 30 Months of Follow-up0
SecondaryPharmacodynamics: Number of Participants With Peripheral Blood B-cell Recovery

B-cell recovery was defined as a CD19 result \>= 0.07 × 10\^9/L, where CD19 was previously depleted. B-cell recovery was only considered possible following the last dose of study treatment. The number of participants with B-cell recovery from End of Treatment to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) \[PD before B-cell recovery or PD within 45 days after recovery\] or Recovery without PD. PD required one of the following: 50% increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50% increase in the longest diameter of any previous site of lymphadenopathy, 50% increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.

Time frame:
Up to approximately 30 months
Reported as:
Number · Participants
Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Recovery
ParticipantsObinutuzumab + CHOP
Within 6 Months Follow-up (FU): Recovery with Progressive Disease (PD)0
Within 6 Months FU: Recovery without PD0
Within 6-12 Months FU: Recovery with PD0
Within 6-12 Months FU: Recovery without PD4
Within 12-18 Months FU: Recovery with PD0
Within 12-18 Months FU: Recovery without PD1
Within 18-24 Months FU: Recovery with PD1
Within 18-24 Months FU: Recovery without PD0
Within 24-30 Months FU: Recovery with PD0
Within 24-30 Months FU: Recovery without PD0
After 30 Months FU: Recovery with PD0

Adverse events

Collected over From the first dose of study treatment to clinical data cut-off: 23 December 2016 (up to 5 years, 4 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obinutuzumab + CHOP—38/100 (38%)100/100 (100%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventObinutuzumab + CHOP
Febrile neutropeniaBlood and lymphatic system disorders14/100
PneumoniaInfections and infestations6/100
SepsisInfections and infestations2/100
DiarrhoeaGastrointestinal disorders2/100
HypoxiaRespiratory, thoracic and mediastinal disorders2/100
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/100
DehydrationMetabolism and nutrition disorders2/100
Mental status changesPsychiatric disorders2/100
Catheter site cellulitisInfections and infestations1/100
CellulitisInfections and infestations1/100
Most frequent other events
Showing 10 of 60
Most frequent other events
EventObinutuzumab + CHOP
NauseaGastrointestinal disorders59/100
Infusion related reactionInjury, poisoning and procedural complications56/100
FatigueGeneral disorders48/100
ChillsGeneral disorders41/100
AlopeciaSkin and subcutaneous tissue disorders40/100
NeutropeniaBlood and lymphatic system disorders40/100
DiarrhoeaGastrointestinal disorders38/100
VomitingGastrointestinal disorders31/100
ConstipationGastrointestinal disorders29/100
DyspnoeaRespiratory, thoracic and mediastinal disorders28/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)Obinutuzumab + CHOP
Mean57.9 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)Obinutuzumab + CHOP
Female43
Male57
08

Study locations

38 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • cCare
    Encinitas, California 92024, United States
  • University of Colorado Cancer Center Department of Hematology
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Ctr - Denver (Williams)
    Denver, Colorado 80218, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • Florida Cancer Specialists; Department of Oncology
    Fort Myers, Florida 33901-8101, United States
  • Florida Cancer Specialists; Saint Petersburg
    St. Petersburg, Florida 33719, United States
  • Northwest Georgia Oncology Centers PC - Marietta
    Marietta, Georgia 30060, United States
  • Kootenai Medical Center
    Coeur d'Alene, Idaho 83814, United States
  • Northwestern University; Robert H. Lurie Comp Can Ctr
    Chicago, Illinois 60611, United States
  • Onc Hem Assoc of Central IL
    Peoria, Illinois 61615-7828, United States
  • McFarland Clinic
    Ames, Iowa 50010, United States
  • Jewish Cancer Care
    Louisville, Kentucky 40245, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-0934, United States
  • MT Cancer Inst Fndtn; MT Can Spec
    Missoula, Montana 59802, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89128, United States
  • MSKCC at Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Memorial Sloan-Kettering; Cancer Center
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • MSKCC at Mercy Med Ctr
    Rockville Centre, New York 11570, United States
  • MSKCC at Sleepy Hollow
    Sleepy Hollow, New York 10591, United States
  • Emerywood Hematology and Onc
    High Point, North Carolina 27262, United States
  • Willamette Valley Cancer Insitute and Research Center
    Springfield, Oregon 97477, United States
  • Medical University of SC (MUSC)
    Charleston, South Carolina 29425, United States
  • SCRI-Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Onc & Hem Assoc; USO Cent Pharm
    Fort Worth, Texas 76177, United States
  • MD Anderson Cancer Center Department of Lymphoma & Myeloma
    Houston, Texas 77030, United States
  • Methodist Hospital Research Institute
    Houston, Texas 77030, United States
  • Cancer Therapy & Research Center
    San Antonio, Texas 78229, United States
  • USO - Tyler Cancer Ctr
    Tyler, Texas 75702, United States
  • Blue Ridge Cancer Care - Roanoke
    Roanoke, Virginia 24014, United States
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
  • Northwest Cancer Specialists - Vancouver
    Vancouver, Washington 98684, United States
  • Yakima Valley Memorial Hospital/North Star Lodge
    Yakima, Washington 98902, United States
  • Aurora Bay Care Medical Center
    Green Bay, Wisconsin 54311, United States
09

References and documents

Publications

  • Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12. PubMed 31050355 ↗
  • Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leuk Lymphoma. 2019 Apr;60(4):894-903. doi: 10.1080/10428194.2018.1515940. Epub 2018 Oct 2. PubMed 30277102 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Dec 2013, 28 months.

Results were first posted in Mar 2015, 1 year 2 months after primary completion.

Of 122 phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 77. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2011
First posted
Aug 11, 2011
StartActual
Aug 31, 2011
Primary completionActual
Dec 31, 2013
CompletionActual
Dec 23, 2016
Results first posted
Mar 19, 2015
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Sep 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Florida Cancer Specialists; Saint Petersburg · St. Petersburg, United States
Show 1 removed
  • Florida Cancer Specialists; Saint Petersburg · Saint Petersburg, United States
Sep 29, 2026
Secondary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedPharmacodynamics: Number of Participants With Peripheral Blood CD19-positive B-cell CountDepletionTime frame: Up to approximately 24 months → From end of study treatment up to approximately 30 months
  • AddedPharmacodynamics: Number of Participants With Peripheral Blood B-cell RecoveryTime frame: Up to approximately 30 months
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Posted results revised
    1 site added, 1 site removed
    Show site
    • Florida Cancer Specialists; Saint Petersburg · St. Petersburg, United States
    Show 1 removed
    • Florida Cancer Specialists; Saint Petersburg · Saint Petersburg, United States
    Secondary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedPharmacodynamics: Number of Participants With Peripheral Blood CD19-positive B-cell CountDepletionTime frame: Up to approximately 24 months → From end of study treatment up to approximately 30 months
    • AddedPharmacodynamics: Number of Participants With Peripheral Blood B-cell RecoveryTime frame: Up to approximately 30 months
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01414855
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Aug 11, 2011
Start date
Aug 31, 2011
Primary completion
Dec 31, 2013
Completion
Dec 23, 2016
Results posted
Mar 19, 2015
Last update
Sep 29, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion